Meghana Kumar, MD
Endocrinology, Diabetes & Metabolism · Conyers, GANPI 1043639545
Payments from drug & device makers
Across 206 payments — averaging $37.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$4K
- Novo Nordisk$808
- Lilly USA, LLC$561
- BETA Bionics, Inc.$398
- Abbott$250
- Radius Health, Inc.$180
- plus $1K from 22 others
What the payments were for
- Consulting fees$1,70022%
- Travel & lodging$1,60521%
- Food & beverage$4,19855%
- Education$851%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 24 | $4,117 |
| Novo Nordisk | 59 | $808 |
| Lilly USA, LLC | 29 | $561 |
| BETA Bionics, Inc. | 3 | $398 |
| Abbott | 15 | $250 |
| Radius Health, Inc. | 9 | $180 |
| Xeris Pharmaceuticals, Inc. | 7 | $146 |
| Medtronic | 4 | $131 |
| AstraZeneca(2 entities) | 8 | $128 |
| Sanofi-aventis U.S. LLC | 6 | $120 |
| Insulet Corporation | 5 | $105 |
| Boehringer Ingelheim | 5 | $92 |
| IBSA Pharma Inc. | 4 | $73 |
| Amgen | 3 | $73 |
| Bayer | 3 | $59 |
| AbbVie | 4 | $55 |
| Ultragenyx Pharmaceutical Inc. | 2 | $54 |
| Merck | 3 | $51 |
| Dexcom, Inc. | 3 | $44 |
| Tandem Diabetes Care, Inc. | 2 | $42 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
| Novartis | 1 | $20 |
| GRT US Holding, Inc. | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Nevro Corp. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$3,439
- iLet Bionic Pancreas$1,193
How this compares
$7,648 in reported general payments places this provider in the 70th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 616 | $1,032,989 |
| MounjaroTirzepatide | 289 | $456,478 |
| JardianceEmpagliflozin | 133 | $168,339 |
| JanuviaSitagliptin Phosphate | 142 | $139,795 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 69 | $125,229 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 53 | $97,572 |
| FarxigaDapagliflozin Propanediol | 75 | $93,742 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 53 | $88,075 |
| TrulicityDulaglutide | 59 | $86,874 |
| AfrezzaInsulin Regular, Human | 52 | $84,048 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 28 | $55,934 |
| Humalog Kwikpen U-200Insulin Lispro | 23 | $55,554 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 46 | $54,003 |
| TymlosAbaloparatide | 20 | $53,490 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 39 | $46,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $808 | $1,183,431725 claims |
| Lilly USA, LLCMounjaro, Trulicity | $561 | $543,352348 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Glyxambi, Synjardy | $92 | $319,188260 claims |
| MerckJanuvia, Janumet Xr | $51 | $165,824161 claims |
| AstraZenecaFarxiga | $128 | $93,74275 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $120 | $88,07553 claims |
| Mannkind CorporationAfrezza | $4,117 | $84,04852 claims |
| Radius Health, Inc.Tymlos | $180 | $53,49020 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $3,894427 claims |
| AbbVieSynthroid | $55 | $3,78529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Conyers
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- John ReedRoswell$5.7M
- Thomas JonesMacon$4.8M
- Steven LeichterColumbus$3.1M
- Jason BernerJasper$2.6M
- Ashwini GoreMacon$2.6M
- Adeniyi OdugbesanLawrenceville$1.8M
- David RobertsonAtlanta$1.7M
- Thomas ZieglerAtlanta$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.